Adaptin Bio Reports $1.2 Million Net Loss in Q2 2026, Decreases R&D Expenses by 59%

Adaptin Bio, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $1.2 million, a 21% decrease from the $1.5 million loss recorded in the same period of 2025. For the first half of 2026, the company’s net loss totaled $2.35 million, compared to $2.12 million for the first half of 2025. The reduction in losses is attributed to a significant decrease in research and development expenses, which fell by 59% to $138,167 in the second quarter, primarily due to the nearing completion of its assay development program and reduced costs associated with sponsored research agreements with Duke University.

Total operating expenses for the second quarter of 2026 were $1.2 million, down from $1.5 million in the prior year, reflecting a 21% reduction. General and administrative expenses also decreased by 10% to $1.06 million, driven by lower legal and professional service costs, although this was partially offset by increased compensation expenses. The company’s cash and cash equivalents increased to $670,488 as of June 30, 2026, up from $459,174 at the end of 2025, indicating improved liquidity.

In terms of strategic developments, Adaptin Bio has been actively pursuing its clinical programs, particularly focusing on APTN-101, a bispecific T cell engager designed to target malignant glioma. The company has initiated preparations for a Phase I clinical trial, which is a significant step in its product development pipeline. Additionally, Adaptin Bio has engaged in several private placements, raising funds through the issuance of common stock and warrants, which has contributed to its cash position.

Operationally, the company has seen a modest increase in its employee headcount, reflecting its ongoing efforts to build a team capable of supporting its clinical and operational objectives. As of June 30, 2026, Adaptin Bio had 9,053,279 shares of common stock outstanding, an increase from 8,655,829 shares at the end of 2025, indicating ongoing capital raising efforts. The company continues to face challenges related to its accumulated deficit, which stood at $11.64 million, and it has expressed substantial doubt about its ability to continue as a going concern without additional funding.

Looking ahead, Adaptin Bio anticipates continued operating losses as it invests in the development of its product candidates. The company plans to fund its operations through existing cash reserves and potential future equity offerings or debt financing. However, it acknowledges the uncertainty surrounding its ability to secure additional funding and the potential impact of macroeconomic conditions on its financial stability. The management remains focused on advancing its clinical programs while navigating the complexities of the biopharmaceutical landscape.